Melo Bisneto, A.V., Fernandes, A.S., Silva, L.D.C., Silva, L.S., Araújo, D.P., Santos, I.C.D., Melo, M.D.R., Silva, R.R.D.S., Franchi, L.P., Cardoso, C.G., Silveira-Lacerda, E.P., Carneiro, C.C., Teixeira, C.S., Chen-Chen, L. (2024). Dioclea violacea lectin inhibits tumorigenesis and tumor angiogenesis in vivo.  Biochimie 222(): 18--27.

FBrf0259701

Research paper

Dioclea violacea seed mannose-binding lectin (DvL) has attracted considerable attention because of its interesting biological activities, including antitumor, antioxidant, and anti-inflammatory activities. This study evaluated the cytotoxic effect of DvL on tumor and normal cells using the mitochondrial activity reduction (MTT) assay, the carcinogenic and anti-carcinogenic activity by the epithelial tumor test (ETT) in Drosophila melanogaster, and the anti-angiogenic effect by the chick embryo chorioallantoic membrane (CAM) assay. Data demonstrated that DvL promoted strong selective cytotoxicity against tumor cell lines, especially A549 and S180 cells, whereas normal cell lines were weakly affected. Furthermore, DvL did not promote carcinogenesis in D. melanogaster at any concentration tested, but modulated DXR-induced carcinogenesis at the highest concentrations tested. In the CAM and immunohistochemical assays, DvL inhibited sarcoma 180-induced angiogenesis and promoted the reduction of VEGF and TGF-β levels at all concentrations tested. Therefore, our results demonstrated that DvL is a potent anticancer, anti-angiogenic, and selective cytotoxic agent for tumor cells, suggesting its potential application as a prototype molecule for the development of new drugs with chemoprotective and/or antitumor effects.